Figure 2.

DLX3 expression is upregulated by PKCα activation in vivo. (a) Immunohistochemical staining of TPA-treated WT and K5-PKCα transgenic skin with antibodies against KRT5 and DLX3 or KRT5 and Loricrin (LOR). Scale bar, 20 μm. (b) Bar graph showing the number of DLX3-positive cells normalized versus the nuclei in WT and K5-PKCα skin treated with TPA or acetone (control). DLX3-positive cells and the number of nuclei in each section were determined by ImageJ software analysis of the labeled particles. Data are presented as mean±S.D. of three different areas from three independent mice for each condition. ***P<0.001. (c) Relative expression level of DLX3 and c-Fos in WT or K5-PKCα primary keratinocytes treated with TPA at 1 and 6 h. (d) DLX3 expression level in cultured keratinocytes transduced with Ad-AFOS or Ad-Cntl vectors at 48 h. For all panels: **P<0.01, ***P<0.001 and the results are shown as mean±S.D. of three independent experiments